Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST ‐2 Landmark Analysis of Survival
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14321 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Helen Ajufo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrimidines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Swedish Orphan Biovitrum, CTI Biopharma.
Abstract (Originalsprache)
Spleen volume reduction (SVR) is a key endpoint in inhibitors of Janus kinase (JAK) inhibitor studies. Retrospective analyses have demonstrated an association between SVR and improved overall survival (OS) among patients treated with ruxolitinib with a platelet count > 100 × 10 9 /L. Whether this association occurs in patients with thrombocytopenia is unclear. Pacritinib, a JAK2/IRAK1/ACVR1 inhibitor, demonstrated improved SVR versus best available therapy (BAT [best available therapy]; including ruxolitinib) in patients with myelofibrosis and platelet counts ≤ 100 × 10 9 /L in the PERSIST‐2 study. Patients on study at the start of the 12‐week SVR window on pacritinib 200 mg twice daily or BAT were included. OS was evaluated among SVR responders versus non‐responders using different SVR thresholds (≥ 35%, ≥ 20%, ≥ 10%, and > 0%). Among patients on pacritinib ( n = 89), SVR ≥ 10% demonstrated the greatest separation in OS curves between responders and non‐responders (HR, 0.00; 95% CI, 0.00–0.14; p < 0.01), though SVR ≥ 0% and SVR ≥ 20% were also associated with improved OS. No SVR threshold conferred OS benefit on BAT ( n = 84), including ruxolitinib ( n = 39). In patients with myelofibrosis and platelets ≤ 100 × 10 9 /L, achieving SVR on pacritinib, but not BAT (including ruxolitinib), was associated with significant OS benefit, suggesting that pacritinib may offer a unique survival advantage in patients with myelofibrosis and thrombocytopenia who achieve any SVR. Trial Registration: ClinicalTrials.gov number: NCT02055781
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Guy's and St Thomas' NHS Trust, London, UK.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia s. Orsola-Malpighi, Bologna, Italy.
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Mayo Clinic, Phoenix, Arizona, USA.
- Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
Förderung
- NCI NIH HHS
- Swedish Orphan Biovitrum
- CTI Biopharma
Zitieren
APA
Ajufo, H., Bewersdorf, J. P., Harrison, C., Palandri, F., Mascarenhas, J., Palmer, J., Gerds, A., Kiladjian, J. J., Buckley, S., Derkach, A., Roman-Torres, K., & Rampal, R. K. (2025). Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST ‐2 Landmark Analysis of Survival. European Journal of Haematology. https://doi.org/10.1111/ejh.14321
Vancouver
Ajufo H, Bewersdorf JP, Harrison C, Palandri F, Mascarenhas J, Palmer J, et al. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST ‐2 Landmark Analysis of Survival. European Journal of Haematology. 2025. doi:10.1111/ejh.14321
BibTeX
@article{Ajufo2025,
author = {Ajufo, Helen and Bewersdorf, Jan Philipp and Harrison, Claire and Palandri, Francesca and Mascarenhas, John and Palmer, Jeanne and Gerds, Aaron and Kiladjian, Jean-Jacques and Buckley, Sarah and Derkach, Andriy and Roman-Torres, Karisse and Rampal, Raajit K},
title = {Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST ‐2 Landmark Analysis of Survival},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14321}
}
EUVIMED